This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR.Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. Journal of the American Academy of Dermatology 58: 125-135, No. 1, Jan 2008
Rights and permissions
About this article
Cite this article
Infliximab and adalimumab come out on top for psoriasis. Pharmacoecon. Outcomes News 548, 6 (2008). https://doi.org/10.2165/00151234-200805480-00014
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805480-00014